University Health Systems Texas Diabetic Institute
Welcome,         Profile    Billing    Logout  
 5 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cersosimo, Eugenio
NCT02981966: Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Completed
4
32
US
Dapagliflozin, Farxiga, Placebo
The University of Texas Health Science Center at San Antonio, AstraZeneca
Diabetes Mellitus, Type 2
04/22
05/23
NCT02981069: Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

Completed
4
90
US
Dapagliflozin, Farxiga, Exenatide, Byetta, Bydureon, Placebo
The University of Texas Health Science Center at San Antonio, AstraZeneca
Diabetes Mellitus, Type 2
07/22
03/23
NCT03953963: Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

Recruiting
N/A
12
US
HydraSolve T2D™
Medality Medical
Diabetes Mellitus, Type 2, Insulin Resistance
07/21
03/22
NCT02969798: Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Recruiting
N/A
700
US
Dapagliflozin, farxiga, Saxagliptin, onglyza, Pioglitazone, actos, Metformin, glucophage
The University of Texas Health Science Center at San Antonio, American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
03/26
07/27

Download Options